Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and welcome to Arcudis Biotherapeutics 2025 First Quarter Financial Results Conference Call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the call over to Amanda Sheldon. Please go ahead. Thank you, Heidi. Good afternoon, everyone, and thank you for joining us today to review our first quarter 2025 financial results and business update. Slides for today's call are available on the investor section of the Arcutus website. On the call today are Frank Watanabe, President and CEO, Patrick Burnett, Chief Medical Officer, Todd Edwards, Chief Commercial Officer, and Latha Virovan, Chief Financial Officer. I'd like to remind everyone that we will be making forward-looking statements during this call. These statements are subject to certain risks and uncertainties, and our actual results may differ. We encourage you to review all the company's filings with the Securities and Exchange Commission, including descriptions of our business and risk factors. With that, let me hand the call over to Frank. Thank you, Amanda, and thank you to everyone for joining us today. Before I delve into the quarterly details, I want to take a moment to thank David Topper who will retire in a couple of weeks, for his many important contributions to Arcutis, both in his time as our CFO and during his many years as a consultant to our company. We wish him all the best in this next stage of life. And I'm very pleased to welcome Lata Verovan to our first earnings call as our CFO, a role she officially assumed this morning. Lata has been an integral part of our team for many years, and she is fully prepared to step ...